Global pharmaceutical company Lupin Limited recently announced that the U.S. FDA has accepted its aBLA for a proposed pegfilgrastim biosimilar (reference product Neulasta®).  Lupin reported that the aBLA submission was supported by similarity data from analytical, pharmacokinetic, pharmacodynamic and immunogenicity studies.  Company CEO Vinita Gupta commented, “FDA’s acceptance of our BLA is a significant achievement and demonstrates our commitment to delivering products which increase access in areas of substantial medical need.  This BLA expands our oncology portfolio, an area of increasing focus for Lupin.  We look forward to the opportunity to bring affordable biologic options to patients and increasing access to this important treatment.”  Lupin is headquartered in Mumbai, India and develops and commercializes a range of branded and generic pharmaceutical products.